Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to fund development from preclinical stage through Phase 1 over three-year period A lower-dose, freeze-dried, pandemic influenza … [Read more…]
